Literature DB >> 15926759

Total costs of IBS: employer and managed care perspective.

Brooks Cash1, Sean Sullivan, Victoria Barghout.   

Abstract

Irritable bowel syndrome (IBS) is a common gastrointestinal motility disorder that typically affects persons of working age and is costly to employers. The financial burden attributable to the direct (use of healthcare resources) and indirect (missed days from work [absenteeism] and loss of productivity while at work [presenteeism]) costs of IBS is similar to that of other common long-term medical disorders, such as asthma, migraine, hypertension, and congestive heart failure. The symptoms of IBS are significantly bothersome and place a substantial burden on the personal and working lives of patients. As with other long-term medical conditions that have a significant impact on productivity, directed efforts by employers can address IBS in the workplace and thereby potentially decrease its impact. In this article, the symptoms of IBS and its impact on patients and on society as a whole are discussed; options are outlined by which employers can help reduce the total costs of IBS, including lost productivity (both absenteeism and presenteeism), in the workplace.

Entities:  

Mesh:

Year:  2005        PMID: 15926759

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  33 in total

Review 1.  Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches.

Authors:  Gerald Holtmann; Dietmar Schrenk; Ahmed Madisch; Hans D Allescher; Gudrun Ulrich-Merzenich; Fermin Mearin; Dominique Larrey; Peter Malfertheiner
Journal:  Dig Dis       Date:  2019-11-26       Impact factor: 2.404

2.  Fecal incontinence in irritable bowel syndrome: Prevalence and associated factors in Swedish and American patients.

Authors:  M Simrén; O S Palsson; S Heymen; A Bajor; H Törnblom; W E Whitehead
Journal:  Neurogastroenterol Motil       Date:  2016-08-31       Impact factor: 3.598

3.  Snapshot of an integrated psychosocial gastroenterology service.

Authors:  Sarah W Kinsinger; Sarah Ballou; Laurie Keefer
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

4.  Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials.

Authors:  Jessica L Buono; Stavros Tourkodimitris; Phil Sarocco; Jeffrey M Johnston; Robyn T Carson
Journal:  Am Health Drug Benefits       Date:  2014-08

5.  Different faces of gastroparesis.

Authors:  Klaus Bielefeldt; Naeem Raza; Susan L Zickmund
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

Review 6.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

7.  Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors?

Authors:  Savio C Reddymasu; Sandra Sostarich; Richard W McCallum
Journal:  BMC Gastroenterol       Date:  2010-02-22       Impact factor: 3.067

8.  Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions.

Authors:  Monica E Jarrett; Kevin C Cain; Robert L Burr; Vicky L Hertig; Sheldon N Rosen; Margaret M Heitkemper
Journal:  Am J Gastroenterol       Date:  2009-08-18       Impact factor: 10.864

Review 9.  Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide.

Authors:  Siegfried W B Yu; Satish S C Rao
Journal:  Therap Adv Gastroenterol       Date:  2014-09       Impact factor: 4.409

10.  An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D.

Authors:  Brian E Lacy; William D Chey; Lin Chang
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.